Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extended-release dipyridamole/aspirin.

P S Hervey1, K L Goa

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand.

Drugs
|September 24, 1999
PubMed
Summary

Extended-release dipyridamole/aspirin significantly improved secondary stroke prevention compared to monotherapy. This combination therapy demonstrated enhanced efficacy with manageable side effects, offering a cost-effective treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Follitropin alpha in infertility: a review.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Neurology

Background:

  • Dipyridamole and aspirin are antiplatelet agents with distinct mechanisms.
  • Combining extended-release dipyridamole with aspirin offers synergistic antithrombotic effects.
  • Previous research indicated potential benefits in preventing thrombotic events.

Purpose of the Study:

  • To evaluate the efficacy and safety of fixed-dose extended-release dipyridamole/aspirin for secondary stroke prevention.
  • To compare the combination therapy against monotherapy with either agent.
  • To assess the pharmacoeconomic impact of the combination therapy.

Main Methods:

  • A large clinical trial involving patients with prior stroke or transient ischemic attack.
  • Twice-daily oral administration of extended-release dipyridamole/aspirin (400/50 mg).
  • Assessment of combined endpoints including stroke and death, and analysis of adverse events.

Main Results:

  • The combination therapy was twice as effective as monotherapy in secondary stroke prevention.
  • No significant impact on plasma concentrations of either agent when coadministered.
  • Adverse events were generally mild, with increased incidence of bleeding and headache compared to monotherapy.

Conclusions:

  • Extended-release dipyridamole/aspirin is a highly effective treatment for secondary stroke prevention.
  • The combination therapy presents a favorable safety profile with manageable side effects.
  • Pharmacoeconomic analyses suggest cost savings and cost-effectiveness compared to aspirin monotherapy.

Related Experiment Videos